Threshold to Present at the 10th Annual JMP Securities Research Conference


REDWOOD CITY, Calif., May 9, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the 10th Annual JMP Securities Research Conference on Tuesday, May 10, at 4:00 p.m. Pacific Time at the Ritz Carlton in San Francisco, CA. The Company will provide an overview of its clinical development program.

A live webcast of the presentation will be available under the Webcasts section of the Company's website. A replay of the presentation will be archived on the site for 60 days.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).


            

Contact Data